ARMP
Armata Pharmaceuticals, Inc. (ARMP) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Negative cash conversion cycle indicates working-capital efficiency, but ARMP’s subscale profile still trails more established peers with steadier operating leverage.
The company’s ability to fund operations with limited near-term cash needs can support liquidity management, yet peers with stronger balance sheets retain far greater resilience.
Reported return on invested capital is deeply negative, showing capital deployment is destroying value versus peers that at least preserve positive economic returns.
The absence of disclosed gross and operating margins limits evidence of durable unit economics, leaving ARMP structurally weaker than peers with proven margin visibility.
Weaknesses
Current and quick ratios near 0.11 indicate severe short-term liquidity strain, leaving ARMP materially weaker than peers with more flexible working-capital buffers.
Negative net debt to EBITDA and debt-to-equity metrics reflect a balance-sheet structure that is not meaningfully supported by earnings, unlike healthier peer capital structures.
Deeply negative ROIC signals that invested capital is not generating returns, which weakens competitive positioning versus peers that can reinvest profitably.
The lack of visible margin data suggests limited operating scale or disclosure quality, both of which typically trail better-capitalized and more mature peers.
Opportunities
If ARMP can improve liquidity and convert working capital more efficiently, it could narrow the gap with peers that currently enjoy stronger near-term financial flexibility.
A sustained reduction in capital intensity would improve ROIC, allowing ARMP to approach peer economics that support more durable reinvestment capacity.
Any future operating scale-up could improve margin visibility and reduce the structural disadvantage versus peers with established cost absorption.
Because segment concentration data are unavailable, clearer disclosure or portfolio simplification could help investors compare ARMP more favorably against diversified peers.
Threats
Persistent liquidity weakness raises refinancing and dilution risk, leaving ARMP more exposed than peers with stronger current ratios and cash reserves.
Negative ROIC increases the risk that additional capital raises destroy rather than create value, unlike peers with positive returns on invested capital.
If operating performance remains opaque, ARMP may continue to trade at a structural disadvantage versus peers with clearer margin and segment economics.
Limited financial cushion can amplify shocks from demand softness or cost inflation, whereas stronger peers can absorb volatility without immediate balance-sheet stress.
Overall Score
ARMP is structurally weaker than peers because severe liquidity constraints and negative capital returns outweigh any limited working-capital efficiency advantage.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Armata Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
